N6-modification of 7-Deazapurine nucleoside analogues as Anti-Trypanosoma cruzi and anti-Leishmania agents: Structure-activity relationship exploration and In vivo evaluation

Chagas disease and leishmaniasis are two poverty-related neglected tropical diseases that cause high mortality and morbidity. Current treatments suffer from severe limitations and novel, safer and more effective drugs are urgently needed. Both Trypanosoma cruzi and Leishmania are auxotrophic for pur...

Full description

Saved in:
Bibliographic Details
Published in:European journal of medicinal chemistry Vol. 231; p. 114165
Main Authors: Lin, Cai, Jaén Batista, Denise da Gama, Mazzeti, Ana Lia, Donola Girão, Roberson, de Oliveira, Gabriel Melo, Karalic, Izet, Hulpia, Fabian, Soeiro, Maria de Nazaré C., Maes, Louis, Caljon, Guy, Van Calenbergh, Serge
Format: Journal Article
Language:English
Published: Elsevier Masson SAS 05-03-2022
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Chagas disease and leishmaniasis are two poverty-related neglected tropical diseases that cause high mortality and morbidity. Current treatments suffer from severe limitations and novel, safer and more effective drugs are urgently needed. Both Trypanosoma cruzi and Leishmania are auxotrophic for purines and absolutely depend on uptake and assimilation of host purines. This led us to successfully explore purine nucleoside analogues as chemotherapeutic agents against these and other kinetoplastid infections. This study extensively explored the modification of the 6-amino group of tubercidin, a natural product with trypanocidal activity but unacceptable toxicity for clinical use. We found that mono-substitution of the amine with short alkyls elicits potent and selective antitrypanosomal and antileishmanial activity. The methyl analogue 15 displayed the best in vitro activity against both T. cruzi and L. infantum and high selectivity versus host cells. Oral administration for five consecutive days in an acute Chagas disease mouse model resulted in significantly reduced peak parasitemia levels (75, 89 and 96% with 12.5, 25 and 50 mg/kg/day, respectively). as well as increased animal survival rates with the lower doses (83 and 67% for 12.5 and 25 mg/kg/day, respectively). [Display omitted] •N6-modified tubercidin analogues were synthesized and evaluated for activity against Trypanosoma cruzi and Leishmania infantum.•Mono-substitution of the amine with short alkyls elicits potent and selective antitrypanosomal and antileishmanial activity.•The methyl analogue 15 displayed the best in vitro activity against both parasites and high selectivity versus host cells.•Oral administration for five consecutive days in an acute Chagas disease mouse model resulted in significantly reduced peak parasitemia levels, as well as increased animal survival rates.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:0223-5234
1768-3254
DOI:10.1016/j.ejmech.2022.114165